The VALID-ECG study will be a component of HeartBeam’s subsequent 510(k) submission, which will focus on the algorithms that take the 3D VECG signal and synthesize a 12-lead ECG, providing ...

FDA clears heart mapping system that hunts down arrhythmias using only a 12-lead ECG. By Conor Hale Nov 10, 2021 10:37am. arrhythmia cardiovascular disease ...

First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG. Contact Us. Contact Us. Newsroom. Services & Solutions ...

HeartBeam’s synthesised 12-lead electrocardiogram (ECG) has met the clinical endpoints in the VALID-ECG pivotal study, assessing non-life-threatening arrhythmias. In the study, the mean ...

SANTA CLARA, Calif., April 29, 2025--HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology ...

HeartBeam, Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510 application to the U.S. Food ...